Insider Selling: AnaptysBio (NASDAQ:ANAB) CFO Sells 3,363 Shares of Stock

AnaptysBio, Inc. (NASDAQ:ANAB) CFO Dennis Mulroy sold 3,363 shares of the company’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $43.26, for a total value of $145,483.38. Following the completion of the sale, the chief financial officer owned 14,330 shares in the company, valued at $619,915.80. This represents a 19.01% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Dennis Mulroy also recently made the following trade(s):

• On Monday, December 22nd, Dennis Mulroy sold 10,000 shares of AnaptysBio stock. The stock was sold at an average price of $50.00, for a total value of $500,000.00.
• On Tuesday, December 16th, Dennis Mulroy sold 15,725 shares of AnaptysBio stock. The stock was sold at an average price of $44.85, for a total value of $705,266.25.

AnaptysBio Price Performance

AnaptysBio stock traded up $0.71 during mid-day trading on Tuesday, hitting $43.91. 466,030 shares of the company’s stock traded hands, compared to its average volume of 381,205. The firm has a 50 day simple moving average of $42.13 and a two-hundred day simple moving average of $31.12. AnaptysBio, Inc. has a fifty-two week low of $12.21 and a fifty-two week high of $52.47. The stock has a market cap of $1.22 billion, a price-to-earnings ratio of -15.57 and a beta of 0.32.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.52 EPS for the quarter, beating the consensus estimate of ($1.06) by $1.58. The firm had revenue of $76.32 million for the quarter, compared to the consensus estimate of $15.83 million. AnaptysBio had a negative net margin of 49.94% and a negative return on equity of 1,101.24%. On average, research analysts anticipate that AnaptysBio, Inc. will post -6.08 earnings per share for the current fiscal year.

AnaptysBio declared that its Board of Directors has approved a share buyback plan on Friday, November 21st that authorizes the company to repurchase $100.00 million in outstanding shares. This repurchase authorization authorizes the biotechnology company to reacquire up to 9.6% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s board believes its shares are undervalued.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on ANAB. Wedbush restated an “outperform” rating and set a $50.00 price objective on shares of AnaptysBio in a report on Monday, November 24th. Guggenheim reissued a “buy” rating on shares of AnaptysBio in a report on Thursday, December 18th. HC Wainwright reduced their price target on AnaptysBio from $52.00 to $51.00 and set a “buy” rating for the company in a research note on Monday, November 24th. Wells Fargo & Company increased their price objective on AnaptysBio from $51.00 to $81.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 5th. Finally, Stifel Nicolaus reduced their target price on shares of AnaptysBio from $80.00 to $56.00 and set a “buy” rating for the company in a research report on Thursday, December 11th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $55.40.

Institutional Trading of AnaptysBio

A number of institutional investors have recently modified their holdings of ANAB. AQR Capital Management LLC grew its holdings in shares of AnaptysBio by 153.3% during the 1st quarter. AQR Capital Management LLC now owns 30,011 shares of the biotechnology company’s stock worth $558,000 after purchasing an additional 18,165 shares in the last quarter. Exome Asset Management LLC bought a new stake in AnaptysBio during the first quarter worth about $2,168,000. Woodline Partners LP grew its stake in AnaptysBio by 63.1% during the first quarter. Woodline Partners LP now owns 791,023 shares of the biotechnology company’s stock worth $14,705,000 after buying an additional 305,950 shares in the last quarter. Rhumbline Advisers grew its stake in AnaptysBio by 2.7% during the first quarter. Rhumbline Advisers now owns 30,903 shares of the biotechnology company’s stock worth $574,000 after buying an additional 826 shares in the last quarter. Finally, Voya Investment Management LLC bought a new position in AnaptysBio in the 1st quarter valued at about $1,803,000.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.